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TargetingTransport of riboﬂavin (RF) across both the brush border membrane (BBM) and basolateral membrane (BLM)
of the polarized enterocyte occurs via speciﬁc carrier-mediated mechanisms. Although, three human
riboﬂavin transporters (hRFTs), i.e., hRFT-1, hRFT-2 and hRFT-3 are expressed in the intestine, little is known
about the cell surface domain(s) at which these speciﬁc hRFTs are expressed. Here, we used live cell confocal
imaging of intestinal epithelial Caco-2 and renal MDCK cells to show that the hRFT-1 is mainly expressed at
the BLM, hRFT-2 is exclusively expressed at the apical membrane, while hRFT-3 is mostly localized inside
intracellular vesicular structures (with some expression at the BLM). Further the level of hRFT-2 mRNA
expression in Caco-2 cells and in native human intestine is signiﬁcantly higher than that of hRFT-1 and -3;
hRFT-2 was also more efﬁcient in transporting 3H-RF than hRFT-1 and -3. These ﬁndings implied an important
role for hRFT-2 in intestinal RF uptake, a conclusion that was further supported by ﬁndings of hRFT-2 gene-
speciﬁc siRNA knockdown investigation. These results show that members of the hRFT family are
differentially expressed in polarized epithelia, and that the apically expressed hRFT-2 plays a key role in
intestinal RF accumulation.ne protein1
Long Beach, CA 90822, USA.
B.V.Published by Elsevier B.V.1. Introduction
Riboﬂavin (RF; vitamin B2) is an essential micronutrient for
normal cellular growth and function. In its coenzyme forms
[riboﬂavin-5-phosphate and ﬂavin adenosine dinucleotide], the
vitamin plays key metabolic roles in biological oxidation-reduction
reactions involving lipid, carbohydrate and amino acid metabolism, as
well as in cellular metabolism of other water-soluble vitamins [1]. RF
deﬁciency and sub-optimal RF levels occur in conditions like chronic
alcoholism, diabetes mellitus, and inﬂammatory bowel diseases as
well as in the elderly [2–6]. Deﬁciency of RF leads to a variety of
clinical abnormalities that include neurological disorders, anemia,
growth retardation, and skin abnormalities [1,7] as well as an
increased susceptibility to cancer [8].
Mammals, including humans, have lost the capability for de novo
synthesis of RF and obtain the vitamin from exogenous sources via
intestinal absorption. The human intestine encounters RF from twosources: a dietary source (processed and absorbed in the small
intestine), and a bacterial source from the normal large intestine
microﬂora (absorbed in the large intestine) [9–13]. The mechanism of
absorption of free RF has been studied using a variety of human and
animal intestinal preparations [reviewed in Ref. 14]. Collectively,
these studies have shown that absorption of RF in the small and large
intestine is mediated by an efﬁcient and speciﬁc, carrier-mediated
mechanism. Since absorption of a nutrient across polarized intestinal
epithelial cells represents movement across two functionally and
structurally distinct membrane domains [brush border membrane
(BBM) and basolateral membrane (BLM) domains], studies have also
examined the mechanism(s) of RF transport across the individual
membrane domain using puriﬁed membrane vesicles with results
showing a speciﬁc carrier-mediated mechanism existing at each
membrane domain [15–18]. Recently, molecular identity of the RFT
systems that operate in human tissues has been deﬁned. Three human
riboﬂavin transporters, hRFT-1, hRFT-2 and hRFT-3 have been cloned
[19–21] and all were shown to be expressed in the human intestine
[19]. hRFT-1 and -3 share 87% identity at amino acid levels, whereas
hRFT-2 shares 43 and 44% identity with hRFT-1 and -3, respectively
[19]. Little, however, is known about the membrane domain(s) of the
polarized enterocyte at which these different transporters are
3017V.S. Subramanian et al. / Biochimica et Biophysica Acta 1808 (2011) 3016–3021localized. Addressing this issue is crucial for understanding the details
of the intestinal RF absorption process. Here, we investigated this
issue using live cell confocal imaging in conﬂuent monolayers of a
polarized intestinal epithelial Caco-2 and renal epithelial MDCK cell
types. Our ﬁndings demonstrate that hRFT-1 is mainly expressed at
the BLM, while expression of the hRFT-3 occurs predominantly in
intracellular vesicles (with some being at the BLM). Expression of the
hRFT-2, on the other hand, occurs exclusively at the apical membrane
domain [21,22]. These ﬁndings together with functional data
involving both over-expression and selective knockdown with gene-
speciﬁc siRNA, suggest a predominant role for the hRFT-2 in intestinal
RF absorption.
2. Materials and methods
2.1. Materials
GFP-C3 and DsRed-C1 ﬂuorescent protein vectors were from
Clontech (Palo Alto, CA). LAMP1-RFP was obtained from Addgene Inc
(Cambridge, MA). Caco-2, HuTu-80 and MDCK cells were from ATCC
(Manassas, VA). 3H-RF (speciﬁc activity ~12.3 Ci/mmol) was from
Moravek Biochemicals (Brea, CA). DNA oligonucleotides primers
(Table 1) were synthesized by Sigma Genosys (Woodlands, TX).
hRFT-2 gene-speciﬁc siRNA was from Invitrogen (Carlsbad, CA;
Table 1).
2.2. Generation of ﬂuorescent protein fusion constructs
The full-length GFP-hRFT1, GFP-hRFT2, DsRed-hRFT2 and GFP-
hRFT3 were generated by PCR ampliﬁcation using hRFT-1, -2, and -3
gene-speciﬁc primer combinations (Table 1), PCR ampliﬁcation kit
(Clontech, CA) and PCR conditions as described previously [22–24].
The ampliﬁed PCR products for hRFT-1 and -3 and GFP-C3 vector were
digested with Hind III and Sac II. The PCR product for hRFT-2, DsRed-
C1 and GFP-C3 vectors were digested with XhoI/SalI and BamHI. The
digested products were ligated separately for each construct using
rapid DNA ligation kit (Roche Diagnostics, Indianapolis, IN) to
generate in-frame fusion construct with GFP-C3 or DsRed-C1 fused
to NH2- terminus of each full-length construct. The generated fusion
constructs were all veriﬁed by sequencing (Laragen, Los Angeles, CA).
2.3. Cell culture and transient transfection
Caco-2, HuTu-80 and MDCK cells were maintained in minimal
essential medium [(MEM) ATCC, Manassas, VA]. MEM was supple-
mented with fetal bovine serum, glutamine, NaHCO3 and antibiotics
as described before [22–24]. Cells were grown on sterile glass-Table 1
Combination of PCR primers used to prepare the full-length hRFT-1,-2 and -3 constructs of
Construct Forward & Reverse Primers (5’-3’)
GFP-hRFT1[1-448] CCCAAGCTTATGGCAGCACCCACGCT; TCCCCGCGGG
GFP-hRFT2[1-469] CCGCTCGAGATGGCCTTCCTGATGCAC; CGGGATCCG
DsRed-hRFT2[1-469] GCGTCGACATGGCCTTCCTGATGCAC; CGGGATCCG
GFP-hRFT3[1-455] CCCAAGCTTATGGCAGCACCCACGCCCGCC; TCCCCG
Real-time PCR primers
hRFT-1 AAAAGACCTTCCAGAGGGTTG; AGCACCTGTACCAC
hRFT-2 CCTTTCCGAAGTGCCCATC; AGAAGGTGGTGAGGTA
hRFT-3 CCCTGGTCCAGACCCTA; ACACCCATGGCCAGGA
β-actin AGCCAGACCGTCTCCTTGTA; TAGAGAGGGCCCACC
hRFT-2 si RNA sequence
CCG GCG CAC CUG UUC AUC UAU A; UCC UGC CUA ACA GGU CUC UGC UGU U
Table 1 shows the primer sequences and combinations used to generate each construct. Rest
and -3 and XhoI (boldface text)/SalI (italics), and BamHI (underlined text) for hRFT-2 we
C1vectors.bottomed poly-D-lysine coated Petri dishes (MatTek, MA) or on 12
well plates (Corning, NY) and transfected with GFP, GFP-hRFT1, GFP-
hRFT2, DsRed-hRFT2 and GFP-hRFT3 at 95% of conﬂuency with 2-4 μg
of plasmid DNA using Lipofectamine 2000 (Invitrogen, CA) [22,25].
After 24–48 h of transient transfection, cells were imaged on Petri
dishes or used for 3H-RF uptake as described below.2.4. Confocal imaging of ﬂuorescent protein fusion constructs in live cells
Conﬂuent cell monolayer was imaged using a Nikon C-1 confocal
microscope. Green ﬂuorescent protein (GFP) was excited with
488 nm line from an argon ion laser and emitted ﬂuorescence was
monitored with a 515±30 nm short pass ﬁlter (GFP), Red ﬂuorescent
protein (DsRed) was excited with the 543-nm line from an HeNe ion
laser and emitted ﬂuorescence was monitored with a 570±50 nm
long pass ﬁlter. Images were captured using Nikon C-1 software
(Nikon Instruments Inc, NY) [22,25].2.5. siRNA treatment
hRFT-2 gene-speciﬁc siRNA was obtained from Invitrogen (Carls-
bad, CA) with a sequence as listed in Table 1. Caco-2 cells pretreated
with (60 nM) hRFT-2 siRNA or control siRNA (scrambled siRNA) for
48 h and were used for 3H-RF uptake and for RNA isolation to perform
real-time PCR analysis as described below.2.6. 3H-RF uptake assay
3H-RF uptake assays were performed on GFP-hRFT1, GFP-hRFT2
and GFP-hRFT3 transiently expressing HuTu-80 cells, or hRFT-2 gene-
speciﬁc siRNA pretreated Caco-2 cells in Krebs-Ringer buffer (pH 7.4)
containing 3H-RF (0.025 μM) as described previously [22,25]. Protein
content of the cell digest was determined in parallel wells using
protein assay kit (Bio-Rad, CA).2.7. Real-time PCR analysis
Native human small intestinal RNA [pooled from 5 individuals
(Clontech, CA)] or RNA isolated from Caco-2 cells was used for real-
time PCR analysis. cDNA was synthesized from RNA using a reverse
transcriptase kit (Invitrogen, CA) and real-time PCR was performed
utilizing hRFT-1, -2, -3 and β-actin selective primers as described
before [22,26,27].by PCR.
Positions Fragment
(bp) (bp)
GGGCCACAGGGGTCTAC 1-1344 1344
GCTGGACAGTGCAGATTGCA 1-1407 1407
GCTGGACAGTGCAGATTGCA 1-1407 1407
CGGGGAGTCACAGGGGTCTGCACA 1-1365 1365
CTGGAT
GTAGG
ACAC
riction sites HindIII (bold face italics text) and SacII (boldface underlined text for hRFT-1
re added to the primers to allow subsequent sub-cloning into the GFP-C3 or DsRed-
3018 V.S. Subramanian et al. / Biochimica et Biophysica Acta 1808 (2011) 3016–30212.8. Statistical analysis
Uptake data represent the result of three separate experiments
and are expressed as mean±SE in fmol/mg protein/unit time.
Differences between the means of control and full-length con-
structs or siRNA pretreated cells were tested for signiﬁcance level
at pb0.05 using Student's t-test. Confocal imaging and real-time
PCR analysis were performed at least three times on different
samples.
3. Results
3.1. Differential expression of hRFT -1, -2, and -3 in polarized epithelia
First, we examined the targeting of hRFT-1, hRFT-2, and hRFT-3 in
live polarized epithelial cells. Constructs of each full-length riboﬂavin
transporter fused with GFP (GFP-hRFT1, GFP-hRFT2 and GFP-hRFT3)
were transiently transfected into intestinal (Caco-2) and renal
(MDCK) cells. Live cell confocal imaging was then performed 24–
48 h following transfection. Lateral (xy) images of cells expressing
these constructs showed that these transporters are expressed at the
cell surface as well as in intracellular trafﬁcking vesicles in both
Caco-2 and MDCK cells (Fig. 1A and C). Axial (xz) images of theseC. MDCK
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Fig. 1. Polarized membrane localization of GFP-hRFT-1, -2, and -3 in Caco-2 and MDCK cells
indicated constructs. B and D) Average ﬂuorescence intensity at indicated membrane doma
GFP, hTHTR2-GFP and GFP expressing MDCK cells; note the cytosolic expression of GFP alo
expressed with DsRed-hRFT2 and GFP-hRFT1 or DsRed-hRFT2 and GFP-hRFT3 as indicated
were shown for indicated constructs.cells showed that GFP-hRFT1 was mainly expressed at the BLM of
both cell types with some being retained in intracellular vesicular
structures (Fig. 1A and C). Expression of GFP-hRFT1 was similar to
the known basolaterally localized protein hRFC-GFP (Fig. 1E) [23–
25]. In contrast, GFP-hRFT2 was exclusively expressed at the apical
membrane domain of both these cell types (Fig. 1A and C; [22])
which mimicked the known apical targeting of hTHTR2-GFP [23,25]
(Fig. 1E). As to hRFT-3, this transporter was found to be localized
predominantly within intracellular vesicles, although expression was
evident at the BLM of some cells (Fig. 1A and C). Measurement of
ﬂuorescence intensities from Caco-2 and MDCK cells showing
expression at the respective membrane domains was quantiﬁed
and conﬁrmed the differential targeting of the hRFT transporters
(Fig. 1B and D). We also examined the differential cell surface
targeting in single transfected MDCK cell expressing either DsRed-
hRFT2/GFP-hRFT1 (Fig. 1F), or DsRed-hRFT2/ GFP-hRFT3 (Fig. 1G) to
clearly evidence this differential distribution.
As GFP-hRFT3 displayed numerous intracellular trafﬁcking vesicles
in many transfected cells, we investigated the characteristics of these
structures. Co-transfection of GFP-hRFT1, -2, and -3 with LAMP1-RFP
(a late endosomal and lysosomal marker) showed GFP-hRFT1 co-
localized with LAMP1-RFP (Fig. 2A) and in contrast, no signiﬁcant co-
localization was found between GFP-hRFT2 and LAMP1-RFP (Fig. 2B)F
DsRed-hRFT2 OverlayGFP-hRFT1
G
DsRed-hRFT2 OverlayGFP-hRFT3
Apical
Basolateral
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. A and C) Lateral (xy) and axial (xz) sections of Caco-2 and MDCK cells, expression for
ins for all indicated transporters in Caco-2 and MDCK cells (n≥10 cells) [25]. E) hRFC-
ne. F and G) Lateral (xy) and axial (xz) confocal sections of MDCK cells transiently co-
. Scale bar 10 μm. Representative images from at least three independent experiments
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Fig. 2. Subcellular co-localization of GFP-hRFT1, -2, or -3 with LAMP1-RFP in MDCK cells. MDCK cells were transiently co-transfected with GFP-hRFT1, -2, or -3 and LAMP1-RFP.
Representative images from at least three separate experiments were shown for indicated constructs.
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displayed signiﬁcant co-localization with LAMP1-RFP (Fig. 2C). These
results suggests that both basolaterally localized constructs (hRFT-1
and -3) are present on an endosomal population.3.2. Relative expression of hRFTs mRNA in Caco-2 cells and native human
small intestine
To assess the relative amounts of endogenous hRFT-1, -2, and -3
mRNA in well-differentiated Caco-2 cells and native human small
intestine, real-time PCR was performed using gene-speciﬁc primers
(Table 1). Results showed the level of the hRFT-2 mRNA was
signiﬁcantly (pb0.02) higher than the level of mRNA for hRFT-1 and
-3 in Caco-2 cells (Fig. 3A). Similar observations were also obtained
with native human small intestine where expression of hRFT-2 mRNAA. Caco2 cells
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Fig. 3. Relative expression of hRFTs mRNA levels in Caco-2 and in native human small intesti
and native human small intestine (B) using hRFT-1, -2, and -3 gene-speciﬁc primers as de
experiments performed in different occasions. * pb0.001, # pb0.02.was signiﬁcantly higher than that of hRFT-1 (pb0.001) and hRFT-3
(pb0.02) (Fig. 3B).3.3. Relative functionality of hRFT-1, -2, and -3 in RF uptake
Next, we assessed the ability of hRFT-1, -2, and -3 for transporting
RF. For these experiments, an equal amount of cDNA (2 μg/well)
encoding hRFT-1, -2, and -3 was transiently transfected into human
intestinal epithelial HuTu-80 cells (“Materials and methods”),
followed (48 h later) by 3H-RF uptake assays. We chose HuTu-80
cells for these experiments because they are non-polarized yet of
intestinal origin, and thus, show no differential membrane expression
of these transporters (this was veriﬁed by confocal imaging Fig. 4A).
Results showed that over-expression of hRFTs in HuTu-80 cells caused
a signiﬁcant induction in carrier-mediated RF uptake (pb0.01 for all)0
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Fig. 4. Efﬁciency of hRFTs in transporting RF. A) Lateral (xy) sections of confocal images of GFP-hRFT1, -2, -3 and GFP alone expressing HuTu-80 cells B) GFP, GFP-hRFT1, -2, and -3
transiently expressing HuTu-80 cells were incubated in Krebs–Ringer buffer (pH 7.4) containing 3H-RF (0.025 μM) for 3 min at 37 °C. Data are mean±SE of at least three uptake
determinations performed in three different occasions. * pb0.01 and # pb0.03.
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caused by hRFT-2 was markedly higher than both hRFT-1 and hRFT-3
(pb0.03, Fig. 4B).
3.4. Contribution of hRFT-2 toward overall carrier-mediated RF uptake
by intestinal epithelial cells: gene silencing approach
Having established that hRFT-2 was (i) exclusively expressed at
the apical membrane domain, (ii) expressed more abundantly in the
human intestine compared to hRFT-1 and -3, and (iii) displayed a
greater initial rate of 3H-RF uptake, we next examined the relative
contribution of this transporter toward total carrier-mediated RF
uptake process across the apical membrane domain. For this we used
gene-speciﬁc siRNA to knock down hRFT-2 expression in Caco-2
monolayers grown on solid support. Pre-treatment of Caco-2 mono-
layers with hRFT-2 siRNA caused a signiﬁcant (pb0.01; ~56%)
reduction in the levels of hRFT-2 mRNA expression (Fig. 5A). The
reduction only occurred with hRFT-2, mRNA levels of hRFT-1, and -30
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Fig. 5. Effect of gene-speciﬁc hRFT-2 siRNA on the level of expression of hRFT2 and RF upta
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of Fig. 4. Data are mean±SE of at least three separate uptake and PCR determinations perfactually showed a compensatory increase (86% and 160% for hRFT-1
and -3, respectively). We then examined the effect of the hRFT-2
siRNA treatment on initial rate of carrier-mediated 3H-RF (0.025 μM)
uptake. Data revealed a signiﬁcant (pb0.01; ~48%) inhibition in 3H-RF
uptake in hRFT-2 siRNA treated compared to scrambled siRNA treated
cells (Fig. 5B), despite the compensatory increase in expression of
other RF transport isoforms.
4. Discussion
The recent molecular identiﬁcation of hRFTs has provided a
molecular basis for understanding the contributions of each of these
individual transporters to the highly efﬁcient and speciﬁc process of
intestinal RF uptake. Here we show unique targeting of each family
member in polarized cells: hRFT-1 is expressed basolaterally, hRFT-2
is expressed apically [22] and hRFT-3 is distributed between an
endosomal reservoir and the basolateral cell surface. Resolution of this
polarized expression of hRFT family members deﬁnes the likely0
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transport across the apical (hRFT-2) and basolateral (hRFT-1)
membrane domains that have been previously observed in radi-
oligand uptake experiments [15–18]. The apical localization of hRFT-2
and the differential targeting of hRFT-1 basolaterally are immediately
suggestive of a route for vectorial transport of RF from the intestinal
lumen to the bloodstream that is achieved by differential targeting of
discrete transporter isoforms. The existence of a third family member
(hRFT-3) likely provides further customizability for regulation of RF
homeostasis and trans-epithelial transport. The intracellular localiza-
tion of this transporter within a population of structures co-
expressing LAMP-1 is perhaps suggestive of an adaptively regulated
transporter pool that can undergo regulated translocation to/from the
BLM. Further experiments, however, are needed to assess this
possibility.
Quantiﬁcation of endogenous levels of hRFTs mRNAs revealed
higher levels of hRFT-2 compared with hRFT-1 and hRFT-3 in both
native human intestine and Caco-2 cells. This ﬁnding conﬁrms an
earlier observation on the expressionof RFTs in native human intestine
[19]. Further, both gain of function and loss of function analyses
highlighted a dominant contribution of hRFT-2 to cellular 3H-RF
uptake. Speciﬁcally, over-expression of hRFT-2 increased the initial
rate of 3H-RF uptake to a greater extent than the two other hRFTs.
Knockdownof hRFT-2 resulted in a signiﬁcant (~48%) decreased 3H-RF
uptake despite compensatory increases in expression of hRFT-1 and
hRFT-3. Such ﬁndings when considered in conjunction with observa-
tions that the kinetic parameters of RF uptake process by Caco-2 cells
are similar to those displayed by hRFT-2 [28], and that RF deﬁciency
leads to an induction in intestinal RF uptake [28] and in RFT-2
expression (but not RFT-1, [29] unpublished observations from our
laboratory), make it reasonable to conclude that hRFT-2 plays a
predominant role in intestinal RF absorption process.
In summary, hRFT-2 is expressed at the apical membrane domain
and functions to facilitate RF entry into absorptive epithelia.
Expression of hRFT-1 and to some extent hRFT-3, at the BLM suggests
these systems are responsible for regulating RF exit out of absorptive
epithelia (and possibly for RF uptake from blood in the absence of
luminal RF).Acknowledgements
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